The development of the domestic innovative drug industry continues to improve, and the innovation cooperation of local pharmaceutical companies continues to increase

【Pharmaceutical Network Industry News】Benefiting from the rapid growth of China's economy and the new medical reform, China's pharmaceutical market is developing rapidly, which is bringing major opportunities
for the development of innovative drugs for domestic pharmaceutical enterprises.
However, innovative drugs often have high technical barriers, for enterprises that do not have a talent team and a new drug research and development environment in the early stage, independent research and development means high risk, and a little carelessness will accelerate the outfall in the industry reshuffle, so cooperation has become a new trend
in innovative drug research and development.
In recent years, in order to accelerate the research and development and commercialization of innovative drugs, the cooperation between domestic pharmaceutical companies in innovative drugs is increasing
.
On October 11, Heyuan Biotechnology (Shanghai) Co.
, Ltd.
and Shanghai Weimei Gene Technology Co.
, Ltd.
formally signed a strategic cooperation agreement
.
The two sides will rely on their own technology accumulation and resource advantages, with the help of Weimei Gene's AAVMeta vector development platform, break the limitations of conventional serotypes in gene therapy applications, achieve innovative breakthroughs from the underlying technology, and jointly strive to improve the effectiveness, safety and clinical accessibility of gene therapy, and accelerate the development of
precision gene therapy.
On October 10, Fosun Pharma and China Resources Pharmaceutical announced a strategic partnership
.
According to the agreement, the two sides will focus on clinical needs and cutting-edge biotechnology to accelerate the research and development and industrialization
of innovative drugs and high-end medical devices in China.
At the same time, relying on the resource advantages of CR Pharma and Fosun Pharma's new drug research and development and globalization capabilities, the two sides will deepen international cooperation and jointly expand overseas markets
.
It is worth mentioning that in September, Fosun Pharma and Kefipin Pharmaceutical announced a cooperation between the two parties will jointly develop and independently develop the first potassium competitive acid blocker (P-CAB) "Caprasan hydrochloride", which includes all available indications for oral preparations of Keprasin hydrochloride and ordinary injections, and the two sides will cooperate
globally 。 On July 25, Fosun Pharma also announced a strategic cooperation with Real Biologics, in which the two parties will jointly develop and exclusively commercialize Azvudin by its holding subsidiary, Fosun Pharma Industry, in the areas of HIV/AIDS treatment and prevention.
On the whole, in fact, the cooperation between Chinese pharmaceutical companies in innovation has become very frequent, and has changed from the cooperation between the previous generic drug companies to the cooperation
between innovative drug companies.
In this regard, the industry believes that the choice of local innovative drug companies to cooperate with local pharmaceutical companies in terms of products is actually a recognition
of their innovative ability and clinical value itself.
In recent years, China is actively promoting the development of innovative drugs, and has also insisted that innovative drugs need to adhere to clinical value orientation
.
With the development of innovative drugs in China and the increase of R&D efforts of enterprises, there will be more and more
cooperation cases between domestic pharmaceutical companies.
"Through cooperation, enterprises can achieve greater complementarity of advantages, and can share risks, flexibly mobilize resources from both sides, better promote research and development, accelerate the commercialization process, and better benefit more patients
.
" Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.